Test Code HEX4 Glucotetrasaccharides, Random, Urine
Reporting Name
Glucotetrasaccharides, UPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Diagnosing Pompe disease, when used in conjunction with acid alpha-glucosidase enzyme activity assays and molecular genetic analysis of the GAA gene
Monitoring patients with Pompe disease on enzyme replacement therapy
May support the diagnosis and monitoring of other glycogen storage disorders; however, glucotetrasaccharide (Glc4) excretion appears to be less consistently elevated in glycogen storage disorders other than Pompe disease
This test is not useful for carrier screening.
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Ordering Guidance
Additional Testing Requirements
When requested for the diagnosis of Pompe disease (glycogen storage disorder type II), urine glucotetrasaccharide concentrations need to be interpreted in light of the clinical presentation and other laboratory test results, such as blood creatine kinase, alpha-glucosidase (GAA) activity, and GAA genotype.
Necessary Information
1. Patient's age is required.
2. Reason for testing is required.
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Container/Tube: Plastic, 5-mL urine tube
Specimen Volume: 3 mL
Collection Instructions:
1. Collect a random urine specimen.
2. No preservative.
Specimen Type
UrineSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Frozen (preferred) | 87 days | |
Refrigerated | 28 days | ||
Ambient | 14 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
≤14 months: ≤14.9 mmol/mol Cr
≥15 months: ≤4.0 mmol/mol Cr
Interpretation
An elevated excretion of glucotetrasaccharide is indicative of Pompe disease or other glycogen storage disorders.
Enzyme or molecular analysis is required to confirm suspected diagnosis.
Day(s) Performed
Wednesday
Report Available
4 to 10 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82542
82570
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
HEX4 | Glucotetrasaccharides, U | 53868-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
64174 | Glucotetrasaccharides, U | 53868-6 |
BG710 | Reason for Referral | 42349-1 |
BA2896 | Intepretation (HEX4) | 59462-2 |
BA2897 | Reviewed By | 18771-6 |
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.
Testing Algorithm
For more information see Newborn Screen Follow-up for Pompe Disease